María Julia Rendón Salazar
Research Subjects
María Julia Rendón Salazar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Tamara Hernández Hernández
AlergiaMx Mexico City Mexico
3 shared publications - Jimena Prieto‐Gomez
AlergiaMx Mexico City Mexico
2 shared publications - Ricardo Martinez‐Tenopala
AlergiaMx Mexico City Mexico
2 shared publications - Victor Gonzalez-Uribe
AlergiaMx, Benito Juarez, Mexico City, Mexico; Facultad Mexicana de Medicina, Universidad La Salle Mexico, Tlalpan, Mexico City, Mexico
2 shared publications - Zaira Selene Mojica-Gonzalez
AlergiaMx Mexico City Mexico
2 shared publications - Luis Angel Hernandez Zarate
Hospital Infantil de México Federico Gómez México City Mexico
1 shared publication
Latest Publications
- 14 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70462
Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3‐year real‐world cohort study
Background: The timing of clinically meaningful benefit after pediatric sublingual immunotherapy (SLIT) across allergic multimorbidity patterns remains uncertain. We evaluated early and longitudinal response to SLIT in routine care. Methods: This retrospective longitudinal cohort included patients aged 3–17 years who received individualized liquid‐drop SLIT and met prespecified adherence and treatment‐persistence criteria. Assessments were performed at baseline and months 6, 12, 18, 24, and 36. The primary outcome was achievement of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) minimal clinically important difference (MCID; increase ≥0.5 points) at month 6. Results: Among 1208 patients, 1095 had asthma and 954 allergic rhinitis. Overall, 666/1095 (60.8%) achieved month‐6 PAQLQ MCID: 515/671 (76.8%) with asthma plus allergic rhinitis (Asthma+AR), 103/254 (40.6%) with allergic asthma without AR, and 48/170 (28.2%) with asthma, AR, and atopic dermatitis (Asthma+AR + AD). Compared with allergic asthma without AR, adjusted odds of response were higher for Asthma+AR (adjusted odds ratio 4.73, 95% CI 3.47–6.45) and lower for Asthma+AR + AD (0.52, 95% CI 0.34–0.80). By month 36, mean PAQLQ increased by 1.42 points, rhinitis‐related quality‐of‐life scores decreased by 1.89 points, FeNO decreased by 15.7 ppb, and prescribed inhaled corticosteroid dose decreased by 92.6%. Conclusion: Early response to pediatric SLIT differed across clinical allergic multimorbidity patterns, although outcomes continued to improve through 36 months in this selected adherent and treatment‐persistent cohort. image
- 14 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8) , e70462
Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3‐year real‐world cohort study
Background: The timing of clinically meaningful benefit after pediatric sublingual immunotherapy (SLIT) across allergic multimorbidity patterns remains uncertain. We evaluated early and longitudinal response to SLIT in routine care. Methods: This retrospective longitudinal cohort included patients aged 3–17 years who received individualized liquid‐drop SLIT and met prespecified adherence and treatment‐persistence criteria. Assessments were performed at baseline and months 6, 12, 18, 24, and 36. The primary outcome was achievement of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) minimal clinically important difference (MCID; increase ≥0.5 points) at month 6. Results: Among 1208 patients, 1095 had asthma and 954 allergic rhinitis. Overall, 666/1095 (60.8%) achieved month‐6 PAQLQ MCID: 515/671 (76.8%) with asthma plus allergic rhinitis (Asthma+AR), 103/254 (40.6%) with allergic asthma without AR, and 48/170 (28.2%) with asthma, AR, and atopic dermatitis (Asthma+AR + AD). Compared with allergic asthma without AR, adjusted odds of response were higher for Asthma+AR (adjusted odds ratio 4.73, 95% CI 3.47–6.45) and lower for Asthma+AR + AD (0.52, 95% CI 0.34–0.80). By month 36, mean PAQLQ increased by 1.42 points, rhinitis‐related quality‐of‐life scores decreased by 1.89 points, FeNO decreased by 15.7 ppb, and prescribed inhaled corticosteroid dose decreased by 92.6%. Conclusion: Early response to pediatric SLIT differed across clinical allergic multimorbidity patterns, although outcomes continued to improve through 36 months in this selected adherent and treatment‐persistent cohort. image
- Open Access
- 15 February 2026
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 20 (2) , e70172
Breastfeeding Duration and Airway Inflammation in Children With Asthma Living in a Polluted Megacity
Background: Children with asthma living in highly polluted megacities are at increased risk of poor asthma control and airway inflammation. Breastfeeding has immunomodulatory effects, but its potential to buffer pollution‐related inflammation remains understudied. Objective: To evaluate whether breastfeeding duration is associated with asthma control and airway eosinophilic inflammation (FeNO), and whether it modifies the impact of urban air pollution in children with asthma living in Mexico City. Methods: We conducted a multicenter retrospective study (2022–2025) including children aged 6–17 years with physician‐diagnosed asthma. Asthma control (ACT), airway inflammation (FeNO, NIOX VERO), breastfeeding duration (0–12 months), and borough‐level pollution categories (high/medium/low) were evaluated. Multivariable logistic and linear regression models assessed associations and breastfeeding × pollution interactions. Results: A total of 162 children were included (mean age 10.8 years; 51.2% female). Breastfeeding ≥ 6 months was associated with better asthma control (ACT ≥ 20: OR 2.1; 95% CI 1.3–3.5) and significantly lower FeNO (β −0.24; p < 0.01). High‐pollution residence was linked to lower ACT scores and higher FeNO (both p < 0.01). A significant interaction indicated that breastfeeding ≥ 6 months attenuated the detrimental effect of pollution on airway inflammation and asthma control ( p for interaction < 0.05). Conclusions: Prolonged breastfeeding was independently associated with improved asthma control and reduced airway eosinophilic inflammation, partially mitigating the respiratory burden of chronic pollution exposure. Clinical Implications: Breastfeeding may serve as an accessible, low‐cost protective strategy for children with asthma living in polluted urban environments, supporting its integration into respiratory health policies and early‐life preventive care.
- 15 February 2026
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 20 (2) , e70172
Open AccessBreastfeeding Duration and Airway Inflammation in Children With Asthma Living in a Polluted Megacity
Background: Children with asthma living in highly polluted megacities are at increased risk of poor asthma control and airway inflammation. Breastfeeding has immunomodulatory effects, but its potential to buffer pollution‐related inflammation remains understudied. Objective: To evaluate whether breastfeeding duration is associated with asthma control and airway eosinophilic inflammation (FeNO), and whether it modifies the impact of urban air pollution in children with asthma living in Mexico City. Methods: We conducted a multicenter retrospective study (2022–2025) including children aged 6–17 years with physician‐diagnosed asthma. Asthma control (ACT), airway inflammation (FeNO, NIOX VERO), breastfeeding duration (0–12 months), and borough‐level pollution categories (high/medium/low) were evaluated. Multivariable logistic and linear regression models assessed associations and breastfeeding × pollution interactions. Results: A total of 162 children were included (mean age 10.8 years; 51.2% female). Breastfeeding ≥ 6 months was associated with better asthma control (ACT ≥ 20: OR 2.1; 95% CI 1.3–3.5) and significantly lower FeNO (β −0.24; p < 0.01). High‐pollution residence was linked to lower ACT scores and higher FeNO (both p < 0.01). A significant interaction indicated that breastfeeding ≥ 6 months attenuated the detrimental effect of pollution on airway inflammation and asthma control ( p for interaction < 0.05). Conclusions: Prolonged breastfeeding was independently associated with improved asthma control and reduced airway eosinophilic inflammation, partially mitigating the respiratory burden of chronic pollution exposure. Clinical Implications: Breastfeeding may serve as an accessible, low‐cost protective strategy for children with asthma living in polluted urban environments, supporting its integration into respiratory health policies and early‐life preventive care.
- Open Access
- 28 October 2025
- Published by Universidad La Salle, Mexico in Memorias del Concurso Lasallista de Investigación, Desarrollo e innovación
- Vol. 12 (1) , 17-23
Uso de terapia triple con ICS/LABA + LAMA en el tratamiento del asma: evidencia de vida real en centros especializados de América Latina
Se investigó la frecuencia y características clínicas de pacientes asmáticos tratados con terapia triple ICS/LABA/LAMA en centros especializados en asma en América Latina. Se recopilaron datos sociodemo-gráficos, fenotípicos y clínicos de 279 pacientes con asma que recibieron tratamiento en pasos 4 y 5 según GINA, durante al menos un año. Se compararon los resultados clínicos entre quienes recibieron LAMA y quienes no. Se encontró que los pacientes en paso 4 que recibieron ICS/LABA/LAMA mostraron mejor control del asma, mientras que en paso 5, el control fue menor debido a la severidad del cuadro clínico, priorizándose el uso de terapias biológicas. Los hallazgos sugieren que la adición de LAMA puede mejorar el control del asma en pacientes con enfermedad moderada, independientemente de las características fenotípicas. Este estudio aporta evidencia real de centros especializados sobre el uso efectivo de la terapia triple en el manejo del asma moderada a severa.
- 28 October 2025
- Published by Universidad La Salle, Mexico in Memorias del Concurso Lasallista de Investigación, Desarrollo e innovación
- Vol. 12 (1) , 17-23
Open AccessUso de terapia triple con ICS/LABA + LAMA en el tratamiento del asma: evidencia de vida real en centros especializados de América Latina
Se investigó la frecuencia y características clínicas de pacientes asmáticos tratados con terapia triple ICS/LABA/LAMA en centros especializados en asma en América Latina. Se recopilaron datos sociodemo-gráficos, fenotípicos y clínicos de 279 pacientes con asma que recibieron tratamiento en pasos 4 y 5 según GINA, durante al menos un año. Se compararon los resultados clínicos entre quienes recibieron LAMA y quienes no. Se encontró que los pacientes en paso 4 que recibieron ICS/LABA/LAMA mostraron mejor control del asma, mientras que en paso 5, el control fue menor debido a la severidad del cuadro clínico, priorizándose el uso de terapias biológicas. Los hallazgos sugieren que la adición de LAMA puede mejorar el control del asma en pacientes con enfermedad moderada, independientemente de las características fenotípicas. Este estudio aporta evidencia real de centros especializados sobre el uso efectivo de la terapia triple en el manejo del asma moderada a severa.